다우존스 지수

무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.

등록

BMEA

Biomea Fusion (BMEA)

Biomea Fusion Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:BMEA

1 2 3 4 5 6 7 8 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/06/14	05:30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BMEA	Biomea Fusion Inc
2024/06/13	06:08	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BMEA	Biomea Fusion Inc
2024/06/13	05:30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BMEA	Biomea Fusion Inc
2024/06/08	05:02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BMEA	Biomea Fusion Inc
2024/06/07	05:05	GlobeNewswire Inc.	Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold	NASDAQ:BMEA	Biomea Fusion Inc
2024/06/04	05:05	GlobeNewswire Inc.	Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:BMEA	Biomea Fusion Inc
2024/05/30	22:12	GlobeNewswire Inc.	Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes	NASDAQ:BMEA	Biomea Fusion Inc
2024/05/03	05:05	GlobeNewswire Inc.	Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights	NASDAQ:BMEA	Biomea Fusion Inc
2024/05/02	05:10	GlobeNewswire Inc.	Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:BMEA	Biomea Fusion Inc
2024/04/02	05:10	GlobeNewswire Inc.	Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:BMEA	Biomea Fusion Inc
2024/04/01	22:02	GlobeNewswire Inc.	Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219	NASDAQ:BMEA	Biomea Fusion Inc
2024/04/01	22:00	GlobeNewswire Inc.	Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights	NASDAQ:BMEA	Biomea Fusion Inc
2024/03/08	06:02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BMEA	Biomea Fusion Inc
2024/03/06	17:04	GlobeNewswire Inc.	Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function	NASDAQ:BMEA	Biomea Fusion Inc
2024/03/02	06:16	GlobeNewswire Inc.	Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:BMEA	Biomea Fusion Inc
2024/02/13	07:00	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:BMEA	Biomea Fusion Inc
2024/01/19	06:30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BMEA	Biomea Fusion Inc
2024/01/19	06:30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BMEA	Biomea Fusion Inc
2024/01/11	06:06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BMEA	Biomea Fusion Inc
2024/01/10	01:02	GlobeNewswire Inc.	Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference	NASDAQ:BMEA	Biomea Fusion Inc
2024/01/08	23:00	GlobeNewswire Inc.	Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219	NASDAQ:BMEA	Biomea Fusion Inc
2024/01/06	06:02	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:BMEA	Biomea Fusion Inc
2024/01/03	06:05	GlobeNewswire Inc.	Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare Conference	NASDAQ:BMEA	Biomea Fusion Inc
2023/12/11	23:25	GlobeNewswire Inc.	Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at the 2023 ASH	NASDAQ:BMEA	Biomea Fusion Inc
2023/12/10	07:30	GlobeNewswire Inc.	Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts	NASDAQ:BMEA	Biomea Fusion Inc
2023/12/08	23:00	GlobeNewswire Inc.	Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control after 22 Weeks Off Treatment in Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes in a Poster Presentation at the World Congress Insulin Resista	NASDAQ:BMEA	Biomea Fusion Inc
2023/12/07	23:15	GlobeNewswire Inc.	Biomea Fusion to Present Long-Term Follow-Up Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes and Results from Ex-Vivo Human Islet Experiments at the World Congress Insulin Resistance, Diabetes & Cardiovascular Dise	NASDAQ:BMEA	Biomea Fusion Inc
2023/12/05	22:30	GlobeNewswire Inc.	Biomea Fusion Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes	NASDAQ:BMEA	Biomea Fusion Inc
2023/11/27	22:30	GlobeNewswire Inc.	Biomea Fusion Announces Acceptance of Three Abstracts for its Novel Menin Inhibitor Highlighting Durable Glycemic Control in Diabetes Patients at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in 2024	NASDAQ:BMEA	Biomea Fusion Inc
2023/11/16	22:30	GlobeNewswire Inc.	Biomea Fusion Abstract “BMF-219: A Novel Therapeutic Agent to Reestablish Functional Beta Cells and Provide Long-term Glycemic Control" Selected as One of Six Oral Presentations at 21st World Congress Insulin Resistance, Diabetes & Cardiovascular Disease	NASDAQ:BMEA	Biomea Fusion Inc

검색 관련기사 보기:NASDAQ:BMEA

1 2 3 4 5 6 7 8 다음 >>

Invesco QQQ Trust Series 1

Gold vs US Dollar

US Dollar vs Yen

BNP Paribas (QX)

JP Morgan Chase

US Dollar vs Sterling

Deutsche Telekom (QX)

American Express

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관